|
|
|
faculty
|
|
 |
|
| |
Gary
D. Glick
Werner
E. Bachmann Collegiate Professor of Chemistry
Professor of Biological Chemistry, UM Medical School
Ph.D., Columbia University, Postdoctoral Fellow, Harvard University
Organic
Chemistry and Chemical Biology
Phone: (734) 764-4548
E-mail: gglick@umich.edu
Fax:
734 615-8902
ChemBio
Ph.D Program |
|
| |
|
|
|
|
| |
We
apply chemical principles, particularly those of
organic chemistry, to solve problems focused on
human health. Over the past few years, my group
has worked in several areas including anti-DNA
autoantibody structure and function, and the identification
of novel molecular targets and small molecules
for the treatment of autoimmune diseases and cancer.
Anti-DNA
autoantibodies are a hallmark of the autoimmune
disorder systemic lupus erythematosus, and mediate
a kidney inflammation that can be fatal. However,
the DNA molecules recognized by anti-DNA and
their binding properties remain poorly understood.
We have conducted chemical, biochemical, and
genetic studies to investigate the interaction
of pathogenic anti-DNA with ssDNA. Ultimately,
we hope that characterization of anti-DNADNA
interactions will provide insight to advance
diagnosis of lupus.
In
a second area, we are identifying new targets
and small molecules for the treatment of autoimmune
diseases and cancer. Current therapies for these
disorders employ cytotoxic agents that have limited
efficacy and serious side effects. Using diversity-oriented
synthesis, we identified a class of non-anxiolytic,
pro-apoptotic benzodiazepines that treat disease
in animal models of lupus. These compounds
selectively kill pathogenic lymphocytes, and
unlike current therapies, they are not adversely
immunosuppressive.
We
are now exploring the signals that arise as a
result of target binding. These studies should
help to uncover the basis for the selectivity
displayed by these compounds and help to delineate
the specific signals that initiate apoptosis.
Additionally, the target of our benzodiazepines
is a relatively uncharacterized component of
the mitochondrial F1F0-ATPase, and only limited
information about its function within the enzyme
is available. Therefore, we are also using these
compounds to probe the function of this protein
within the F1F0-ATPase using a combination of
biology, organic synthesis, kinetics, and structural
studies of targetdrug interactions.
We have
discovered that our benzodiazepines circumvent
the major mechanisms cancer cells use to become
resistant to therapy. Based on our understanding
of the factors regulating the cellular sensitivity
to our agents, we plan to examine the effects of
these compounds on resistant cancers. These experiments
should demonstrate additional uses for these molecules
and reveal new pathways and targets for additional
drug discovery.
|
| |
AWARDS
- National
Arthritis Foundation Arthritis Investigator
Award
- American Cancer Society Junior
Faculty Research Award
- National Science Foundation
Young Investigator Award
- Camille Dreyfus
Teacher-Scholar Award
- Research
Fellow of the Alfred P. Sloan Foundation
|
| |
REPRESENTATIVE PUBLICATIONS
- Bednarski,
J.J., Lyssiotis, C.A., Roush, R., Boitano,
A.E., Glick, G.D., Opipari, A.W. Jr., Bz-423
Increases the Sensitivity of B Cells to Receptor
Stimulation with Synergistic Effects on Calcium
Signaling and Apoptosis, J. Biol. Chem., 2004,
279, 29615.
- J. Varani, N. Bhagavathula,
H. Scherzer, K. Fay, G. D. Glick, K. Johnson,
S. Kang, and A.W. Opipari, Jr., "Bz-423
Selectively Inhibits Keratinocyte Proliferation
and Reduces Retinoid-Induced Epidermal Hyperplasia
in Organ-Cultured Human Skin". J.
Pharmacol. Exp. Ther. , 2005 , 313 ,
56.
- X.
Chen, K.M. Johnson, A. Boitano, L. Swenson,
A.W. Opipari, Jr, and G.D. Glick, "The Mitochondrial
F 1 F 0 -ATPase is the Molecular Target of
the Immunomodulatory Benzodiazepine Bz-423", Chem.
Biol . 2005 , 12 ,
485.
- C.P.
Price, G.D. Glick, and A.J. Matzger. "Dissecting
the Behavior of a Promiscuous Solvate
Former". Angew.
Chem ., 2006 45 ,
2062-66.
- T.
Sundberg, G.M. Ney, A.W. Opipari,
and G.D. Glick, "The
Immunomodulatory Benzodiazepine Bz-423
Depletes the Oncogene c-Myc by a Novel Post-Translatonal
Mechanism", Cancer
Res ., 2006 66 ,
1755.
- T.
Francis. T. Sundberg, T. Gryndyke, J.
Cleary, A. Opipari, and G.D. Glick. "Identification
of Cytotoxic T Cell Selective 2,5-Benzodiones", Bioorg.
Med. Chem. Lett ., 2006 manuscript
in press.
|
| |
|
|
|
|
|
|